Lv5
850 积分 2024-05-01 加入
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
4个月前
已完结
EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis
4个月前
已完结
Resistance to Immunotherapy in Non-small Cell Lung Cancer: Unraveling Causes, Developing Effective Strategies, and Exploring Potential Breakthroughs
5个月前
已完结
Hallmarks of Cancer: New Dimensions
5个月前
已完结
Catumaxomab: First Approval
5个月前
已关闭